Moreover, investigation of the expression levels of EGFR, PD-L1, and TMEM16A in the early-stage HNSCC is necessary to confirm whether the target therapy we suggested in this review can be adopted in such an early disease. This evidence concerns the gene CD274 and head and neck squamous cell carcinoma.